Suppression of Serum Interferon ‐γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus

ConclusionWhile not diminishing a potential role of IL ‐23, these serum biomarker assessments indicate that IL‐12 blockade has an important role in the mechanism of action of ustekinumab treatment in patients with SLE.

Source: Arthritis and Rheumatology - February 1, 2021 Category: Rheumatology Authors: Matteo Cesaroni, Loqmane Seridi, Matthew J. Loza, Jessica Schreiter, Kristen Sweet, Carol Franks, Keying Ma, Ashley Orillion, Kim Campbell, Robert M. Gordon, Patrick Branigan, Peter Lipsky, Ronald Vollenhoven, Bevra H. Hahn, George C. Tsokos Tags: Brief Report Source Type: research